Related references
Note: Only part of the references are listed.Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease
Zheng Wu et al.
NATURE COMMUNICATIONS (2020)
Immunotherapies in Huntington's disease and alpha-Synucleinopathies
Oluwaseun Fatoba et al.
FRONTIERS IN IMMUNOLOGY (2020)
Huntingtin-Lowering Therapies for Huntington Disease A Review of the Evidence of Potential Benefits and Risks
Blair R. Leavitt et al.
JAMA NEUROLOGY (2020)
Medical, Surgical, and Genetic Treatment of Huntington Disease
Christine M. Stahl et al.
NEUROLOGIC CLINICS (2020)
Huntington's Disease Clinical Trials Corner: April 2020
Filipe B. Rodrigues et al.
JOURNAL OF HUNTINGTONS DISEASE (2020)
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann et al.
LANCET NEUROLOGY (2019)
Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease
Sarah J. Tabrizi et al.
NEURON (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease
Edith L. Pfister et al.
HUMAN GENE THERAPY (2018)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Juliette Hordeaux et al.
MOLECULAR THERAPY (2018)
Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain
Yasunori Matsuzaki et al.
NEUROSCIENCE LETTERS (2018)
Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases
Magdalena Dabrowska et al.
FRONTIERS IN NEUROSCIENCE (2018)
New approaches for brain repair-from rescue to reprogramming
Roger A. Barkers et al.
NATURE (2018)
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease
Su Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
Manaswini Sivaramakrishnan et al.
NATURE COMMUNICATIONS (2017)
Direct Reprogramming of Resident NG2 Glia into Neurons with Properties of Fast-Spiking Parvalbumin-Containing Interneurons
Maria Pereira et al.
STEM CELL REPORTS (2017)
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Marta Garcia-Miralles et al.
JCI INSIGHT (2017)
Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial
Christopher LaGanke et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease
Joao Casaca-Carreira et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts
Kyle D. Fink et al.
CELL TRANSPLANTATION (2016)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial
Samuel Frank et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies
Natalia P. Rocha et al.
MEDIATORS OF INFLAMMATION (2016)
Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease
Arlene I. Ramsingh et al.
HUMAN MOLECULAR GENETICS (2015)
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
Ferdinando Squitieri et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L. Southwell et al.
NEUROBIOLOGY OF DISEASE (2015)
In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry
Olof Torper et al.
CELL REPORTS (2015)
Effects on Murine Behavior and Lifespan of Selectively Decreasing Expression of Mutant Huntingtin Allele by Supt4h Knockdown
Hui-Min Cheng et al.
PLOS GENETICS (2015)
SOX2 Reprograms Resident Astrocytes into Neural Progenitors in the Adult Brain
Wenze Niu et al.
STEM CELL REPORTS (2015)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
Intrajugular Vein Delivery of AAV9-RNAi Prevents Neuropathological Changes and Weight Loss in Huntington's Disease Mice
Brett D. Dufour et al.
MOLECULAR THERAPY (2014)
Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease
Nan Wang et al.
NATURE MEDICINE (2014)
Generation of Human Striatal Neurons by MicroRNA-Dependent Direct Conversion of Fibroblasts
Matheus B. Victor et al.
NEURON (2014)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
Spt4 Is Selectively Required for Transcription of Extended Trinucleotide Repeats
Chia-Rung Liu et al.
CELL (2012)
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2012)
The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2012)
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Mireia Garriga-Canut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
David C. Butler et al.
PLOS ONE (2011)
Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis
Tatsusada Okuno et al.
JOURNAL OF IMMUNOLOGY (2010)
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Mahmoud A. Pouladi et al.
BRAIN (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells
David Mittelman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Maria Bjorkqvist et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Sigma-1 receptor chaperones at the ER-Mitochondrion interface regulate Ca2+ signaling and cell survival
Teruo Hayashi et al.
CELL (2007)
Microglial activation in presymptomatic Huntington's disease gene carriers
Yen F. Tai et al.
BRAIN (2007)
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin
Rona K. Graham et al.
CELL (2006)
Microglial activation correlates with severity in Huntington disease - A clinical and PET study
N. Pavese et al.
NEUROLOGY (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease
TS Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study
YP Deng et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2004)
Inhibition of calpain cleavage of huntingtin reduces toxicity - Accumulation of calpain/caspase fragments in the nucleus
J Gafni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Huntingtin aggregation and toxicity in Huntington's disease
G Bates
LANCET (2003)
Early and progressive accumulation of reactive microglia in the Huntington disease brain
E Sapp et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2001)
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
A Yamamoto et al.
CELL (2000)
Share Paper
